Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (211-220 of 227) with videos related to

Pageof 23
Sort By:
Cancer|July 17, 2020
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trialRobert J Motzer, Bernard Escudier, Saby George, et al.
Journal for Immunotherapy of Cancer|June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
The New England Journal of Medicine|April 17, 2024
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell CarcinomaToni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerScott N Gettinger, Leora Horn, Leena Gandhi, et al.
The New England Journal of Medicine|June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Cancer Cell|March 12, 2021
Progressive immune dysfunction with advancing disease stage in renal cell carcinomaDavid A Braun, Kelly Street, Kelly P Burke, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Pageof 23

Showing results (211-220 of 227) with videos related to

Sort By:
Pageof 23
Cancer|July 17, 2020
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trialRobert J Motzer, Bernard Escudier, Saby George, et al.
Journal for Immunotherapy of Cancer|June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
The New England Journal of Medicine|April 17, 2024
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell CarcinomaToni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerScott N Gettinger, Leora Horn, Leena Gandhi, et al.
The New England Journal of Medicine|June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Cancer Cell|March 12, 2021
Progressive immune dysfunction with advancing disease stage in renal cell carcinomaDavid A Braun, Kelly Street, Kelly P Burke, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Pageof 23